Fortrea Holdings (FTRE) Net Margin (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Net Margin came in at 1.95% in Q2 2026, up 47.51% on a QoQ basis from 3.71% in Q1 2026.

Fortrea Holdings (FTRE) Net Margin (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 4 years of Net Margin data on file, last reported at 1.95% in Q2 2026.

Quarterly Net Margin changed N/A year-over-year to 1.95% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1.37% (down 150.0% YoY) and the FY2024 annual result came in at 2.11%, down 234.0% from the prior year.
Net Margin climbed to 1.95% in Q2 2026, from 3.71% in the prior quarter.
In the past five years, Net Margin ranged from a high of 8.37% in Q2 2022 to a low of 5.9% in Q2 2024.
A 4-year average of 0.02% and a median of 0.83% in 2023 frame the typical range for Net Margin.
Annual changes were most pronounced in 2023 — Net Margin slumped 766 bps — and 2024, when it soared 265 bps.
Tracing FTRE's Net Margin over 4 years: stood at 2.71% in 2022, then surged by 69 bps to 0.83% in 2023, then surged by 319 bps to 1.82% in 2024, then plunged by 207 bps to 1.95% in 2026.
The last three Net Margin figures came in at 1.95% (Q2 2026), 3.71% (Q1 2026), and 1.82% (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	30.33%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.90%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	30.98%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	12.74%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-3.12%
10	Fortrea Holdings	1.66 Bn	1.49 Bn	139.20 Mn	-1.95%

Download Data